Walleye Trading’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.25M Sell
14,700
-13,500
-48% -$2.07M ﹤0.01% 1639
2025
Q4
$3.89M Buy
28,200
+15,800
+127% +$2.07M 0.01% 1449
2025
Q3
$1.59M Sell
12,400
-5,400
-30% -$659K ﹤0.01% 1962
2025
Q2
$2.15M Buy
17,800
+1,500
+9% +$169K ﹤0.01% 1679
2025
Q1
$1.82M Sell
16,300
-35,000
-68% -$3.73M ﹤0.01% 1698
2024
Q4
$4.99M Buy
51,300
+2,200
+4% +$235K 0.01% 1144
2024
Q3
$5.65M Buy
49,100
+24,500
+100% +$2.78M 0.01% 1069
2024
Q2
$2.62M Sell
24,600
-3,500
-12% -$351K 0.01% 1439
2024
Q1
$2.72M Sell
28,100
-38,100
-58% -$3.91M 0.01% 1534
2023
Q4
$6.68M Sell
66,200
-13,900
-17% -$1.34M 0.01% 1057
2023
Q3
$8.16M Sell
80,100
-151,100
-65% -$15.3M 0.02% 784
2023
Q2
$23.3M Sell
231,200
-297,700
-56% -$29.8M 0.07% 252
2023
Q1
$48.7M Buy
528,900
+75,600
+17% +$6.6M 0.11% 148
2022
Q4
$41.1M Buy
453,300
+163,500
+56% +$13.8M 0.12% 167
2022
Q3
$22M Buy
289,800
+246,500
+569% +$20.4M 0.07% 291
2022
Q2
$3.66M Sell
43,300
-165,800
-79% -$14.5M 0.01% 1219
2022
Q1
$18.3M Sell
209,100
-64,100
-23% -$5.55M 0.06% 377
2021
Q4
$23.9M Buy
273,200
+141,200
+107% +$11.7M 0.08% 256
2021
Q3
$10.8M Buy
132,000
+130,300
+7,665% +$11.7M 0.04% 514
2021
Q2
$155K Sell
1,700
-300
-15% -$26.7K ﹤0.01% 4118
2021
Q1
$171K Sell
2,000
-55,500
-97% -$4.98M ﹤0.01% 3757
2020
Q4
$5.43M Sell
57,500
-18,400
-24% -$1.61M 0.02% 682
2020
Q3
$6.6M Buy
75,900
+62,600
+471% +$5.42M 0.04% 444
2020
Q2
$1.16M Sell
13,300
-4,800
-27% -$414K 0.01% 1530
2020
Q1
$1.49M Sell
18,100
-21,100
-54% -$1.88M 0.01% 1025
2019
Q4
$3.71M Sell
39,200
-14,000
-26% -$1.26M 0.03% 767
2019
Q3
$4.62M Buy
53,200
+21,100
+66% +$1.89M 0.04% 504
2019
Q2
$2.93M Buy
32,100
+16,030
+100% +$1.36M 0.03% 776
2019
Q1
$1.38M Buy
16,070
+4,464
+38% +$358K 0.01% 1370
2018
Q4
$892K Sell
11,606
-447
-4% -$34.8K 0.01% 1843
2018
Q3
$931K Buy
12,053
+7,701
+177% +$569K ﹤0.01% 2154
2018
Q2
$295K Sell
4,352
-12,500
-74% -$863K ﹤0.01% 3309
2018
Q1
$1.22M Sell
16,852
-10,602
-39% -$807K 0.01% 1722
2017
Q4
$2.06K Sell
27,454
-3,013
-10% -$227K 0.01% 1281
2017
Q3
$2.35K Sell
30,467
-15,959
-34% -$1.21M 0.01% 1156
2017
Q2
$3.47K Buy
46,426
+38,168
+462% +$2.71M 0.02% 809
2017
Q1
$549 Sell
8,258
-12,500
-60% -$833K ﹤0.01% 2159
2016
Q4
$1.35M Sell
20,758
-17,744
-46% -$1.15M 0.01% 1275
2016
Q3
$2.72M Buy
38,502
+18,749
+95% +$1.37M 0.02% 751
2016
Q2
$1.47M Buy
19,753
+4,352
+28% +$301K 0.01% 1259
2016
Q1
$999K Buy
15,401
+781
+5% +$53.1K 0.01% 1402
2015
Q4
$1.13M Sell
14,620
-7,030
-32% -$558K 0.01% 1148
2015
Q3
$1.78M Buy
21,650
+2,008
+10% +$179K 0.02% 722
2015
Q2
$1.73M Buy
19,642
+13,504
+220% +$1.24M 0.02% 782
2015
Q1
$542K Sell
6,138
-21,539
-78% -$1.91M 0.01% 1427
2014
Q4
$2.3M Buy
27,677
+3,906
+16% +$324K 0.02% 620
2014
Q3
$2.01M Buy
23,771
+6,361
+37% +$515K 0.02% 450
2014
Q2
$1.41K Buy
17,410
+1,116
+7% +$87.8K 0.02% 598
2014
Q1
$1.25K Sell
16,294
-1,785
-10% -$130K 0.02% 721
2013
Q4
$1.3M Buy
18,079
+17,409
+2,598% +$1.21M 0.01% 927
2013
Q3
$46K Sell
670
-46,090
-99% -$3.05M ﹤0.01% 2294
2013
Q2
$2.96M Buy
+46,760
New +$3.04M 0.03% 442

Other funds holding NVS

Walleye Trading's NVS Position: Q1 2026 in Review

Walleye Trading opened a new position in Novartis (NVS) in Q1 2026: 839 shares worth $128K. The stake represents ﹤0.01% of the portfolio and ranks #3342 among its holdings. This is a return to the name: Walleye Trading previously reported a position in NVS as recently as Q3 2025.

Walleye Trading first reported a position in NVS in Q1 2015 and has held it in 21 quarters since. The position peaked at $4.83M in Q3 2023. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Walleye Trading held 839 shares of Novartis worth $128K as of Q1 2026.
  • Novartis was a new Walleye Trading position in Q1 2026.
  • Novartis made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #3342 holding.
  • Walleye Trading first reported a position in Novartis in Q1 2015 and has held it in 21 quarters since.
  • Walleye Trading's Novartis position peaked at $4.83M in Q3 2023.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.